Metabolic dysfunction and alcohol associated liver disease

MONDO:0957896

A steatotic liver disease characterized by at least one of the five cardiometabolic risk factors for MASLD and alcohol consumption of 140-350g/week (females) or 210-420g/week (males). This disease is distinguished from MASLD by increased alcohol consumption and from ALD by the evidence of one or more of the MASLD cardiometabolic risk factors.

10 clinical trials for this condition and its sub-types, 8 tagged with Metabolic dysfunction and alcohol associated liver disease itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Fatty liver disease (616)

Including sub-types (10) Tagged with Metabolic dysfunction and alcohol associated liver disease (8)

Trials to join now! 3 Not yet recruiting 1 Not yet finished but already full! 3 Completed 3

Zapping the brain to heal the liver: new trial tests TMS for fatty liver

Disease control Not yet recruiting

This study tests whether a non-invasive brain stimulation technique called rTMS can reduce liver fat in people with alcohol-related fatty liver disease (MetALD). 105 participants will receive either personalized rTMS, standard rTMS, or a sham (placebo) treatment over 20 sessions.…

Sponsor: The Affiliated Hospital of Hangzhou Normal University • Aim: Disease control

Last updated Jun 27, 2026 09:03 UTC

Metabolic dysfunction and alcohol associated liver disease

Where it sits in the disease tree

Zapping the brain to heal the liver: new trial tests TMS for fatty liver